Compare National Beverage Corp. (FIZZ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Summit Therapeutics Inc — how do they compare? National Beverage Corp. trades at $30.9 (market cap $2.89B), while Summit Therapeutics Inc trades at $15.4 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 4.2× National Beverage Corp.'s market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| FIZZ | SMMT | |
|---|---|---|
Market Cap | $2.89B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $26.98 |
52-Week Low | $30.53 | $12.55 |
Enterprise Value | $2.60B | $11.39B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
